| Document |
Document Title |
|
WO/1999/001467A2 |
There are described therapeutically active compounds or salts or solvates thereof, hydrolysable in human or animal blood to compounds with reduced therapeutic activity. There is also described a method of identifying a compound capable o...
|
|
WO/1998/050042A1 |
This invention provides a method of providing progestational therapy to a mammal in need thereof which comprises administering a progestationally effective amount of a pharmaceutically acceptable salt of 5$g(a)-pregnan-3$g(b)-ol-20-one 3...
|
|
WO/1998/036733A2 |
A cholinergic agent and/or a calcium channel blocker is administered locally to the anus for the treatment of benign anal disorders, in particular anal fissures and haemorrhoids. The agents induce a reduction in the mean and resting pres...
|
|
WO/1998/035701A1 |
The invention provides a method of targeting a drug to areas of hypoxic and/or ischemic tissue within the body in which the desired drug species is linked to a non-cytotoxic bioreductive carrier. Also provided by the invention are novel ...
|
|
WO/1998/032718A1 |
The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and...
|
|
WO/1998/031352A1 |
A dry powder composition comprising one or more potent pharmaceutically active substances and a carrier substance, all of which are in finely divided form, wherein the formulation has a poured bulk density of from 0.28 to 0.38 g/ml is us...
|
|
WO/1997/041145A1 |
A compound having general formula (I) in which R1 is a member selected from the group consisting of -OCH3, -SCH3, -N(CH3)2, -NHCH3, -CHO, -COCH3 and -CHOHCH3; R2 is a member selected from the group consisting of halogen, alkyl, acyl, hyd...
|
|
WO/1997/039018A1 |
The invention discloses products with formula (I) in which: either R1 stands for halogen, hydroxyl, (C1-C8) alkyloxy or (C1-C12) acyloxy, and R2 represents halogen or hydrogen; or R1 and R2 together form a double bond, Z is selected from...
|
|
WO/1997/034871A1 |
Disclosed are (i) compounds of a steroid, a 'beta'-agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO2 group or a group which stimulates endogenous prod...
|
|
WO/1997/027210A1 |
The invention relates to compounds of formula (I), in which R1, R2, R3, R4, R5, R6, n and X are as defined in the specification, and to pharmaceutical compositions containing them. These compounds are excellent progestogens which are dev...
|
|
WO/1997/022616A1 |
Disclosed is a process for producing the epoxy steroid (1.0) wherein R1 is selected from H, -OH, or C1, and R2 is selected from hydrogen or lower alkyl. The process comprises reacting the triene of Formula (2.0) with a brominating or chl...
|
|
WO/1996/040043A2 |
The invention relates to 3'alpha'-hydroxy, 17-(un)substituted derivatives of the androstane series and 3'alpha'-hydroxy, 21-substituted derivatives of the pregnane series. These derivatives are capable of acting at a recently identified ...
|
|
WO/1996/040727A1 |
The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human vomeropherin, e.g. a 19-nor-pregnane steroid, or a pharmaceutical composition containing a vomerophe...
|
|
WO/1996/034846A1 |
Compounds of 1,3-propane diol linked structure (I), when for use in therapy, where R1 is an acyl or fatty alcohol group derived from a C12-30 preferably C16-30 fatty acid desirably with two or more cis or trans double bonds, and R2 is hy...
|
|
WO/1996/034855A1 |
Compounds of structure (I), and when for use in therapy: where R1 is an acyl group derived from a C16-30 fatty acid with two or more cis or trans double bonds and particularly an n-6 or n-3 series EFA or conjugated linoleic acid, or colu...
|
|
WO/1996/034858A1 |
Niacin as a compound, per se or for use in therapy, of structure (I), where B is -C(=O)- (nicotinic acid) or -CH2-O- (niacin alcohol), the "link" C which is optional is a diol or hydroxy carboxylic acid or dicarboxylic acid residue, and ...
|
|
WO/1996/022303A1 |
The present invention relates to a range of therapeutic compounds conjugated to one to three acyl groups derived from fatty acids. The therapeutic compounds are selected from the following group: 1) the corticosterone family of drugs; 2)...
|
|
WO/1996/016076A1 |
Methods, compositions, and compounds for modulating the GABAA receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.
|
|
WO/1996/003421A1 |
6'alpha'-Hydroxy-21-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidiny
l]-1-piperazinyl]-16'alpha'-methylpregna-1,4,9(11)-triene-3,
20-dione, 6'beta'-hydroxy-21-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl
]-1-piperazinyl]-16'alpha'-methylpregna-1,4,...
|
|
WO/1995/032989A1 |
Described is a process for the regioselective dehydration of 11-hydroxy steroids using PCl5, PCl3, POCl3 or either SO2Cl2 and imidazole, or PPh3 and CCl4. The disclosed process selectively forms 'DELTA'9,11 steroids from either 11-'alpha...
|
|
WO/1995/029186A1 |
The present invention relates to methods and compositions for the transformation of cells. In particular, compositions and methods are disclosed which include combinations of the nucleic acid of interest and polyhydroxylated or polyglyco...
|
|
WO/1995/021617A1 |
Methods, compositions, and compounds for modulating the GABAA receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.
|
|
WO/1995/020567A1 |
A codrug composition of at least two drug compounds covalently linked to one another via a labile bond to form a single codrug composition, and methods of use of the codrug for the treatment of various medical conditions. The codrug may ...
|
|
WO/1995/004535A1 |
The application discloses methods of making medicaments for treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural ...
|
|
WO/1994/027608A1 |
Methods and compositions for interacting with the GABAA receptor complex to induce sleep in humans using certain 5 3alpha-hydroxy-5-reduced steroid derivatives.
|
|
WO/1994/026769A1 |
Novel anti-inflammatory compounds, compositions of these compounds and use of such compounds to treat inflammed ocular tissue are described. The compounds are derivatives and analogues of known steroid compounds (e.g., dexamethasone) and...
|
|
WO/1994/016710A1 |
The present invention relates to a topical composition comprising ketoconazole, an acetonide glucocorticosteroid and a dermatologically acceptable carrier, characterized by a pH above 2.5 and below 6, and a method of preparing said compo...
|
|
WO/1994/014834A1 |
Steroids of formula (I) where -_-_-_-_ is independently at each of the 1,2-, 4,5- and 6,7-positions, a single or double bond; R1 is a straight- or branched-chain C1-4 alkyl or C2-4 alkenyl; R2 is hydrogen or methyl; R3 is C1-7 alkyl, phe...
|
|
WO/1994/013690A1 |
Steroids of formula (I) where --- is a single or double bond; R1 is hydrogen or fluorine; and R2 is propyl or trans-prop-1-enyl, and racemic mixtures and diastereoisomers thereof, processes for their preparation, pharmaceutical compositi...
|
|
WO/1994/011386A1 |
Invented are 17alpha and 17beta-substituted acyl-3-carboxy-3,5-diene analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-alpha-red...
|
|
WO/1994/011004A1 |
Invented are 17alpha and 17beta-substituted acyl-3-carboxy-3,5-diene analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-alpha-red...
|
|
WO/1994/006434A1 |
A method and compound having hydrocortisone and tretinoin is disclosed for the treatment of hair loss. The method also includes identifying any underlying conditions causing hair loss, treating the underlying conditions if possible, admi...
|
|
WO/1994/000125A1 |
Invented are 17alpha and 17beta-alkylketone-3-carboxy aromatic A ring analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-alpha-re...
|
|
WO/1993/022333A1 |
Invented are 17$g(a) and 17$g(b)-substituted acyl-3-carboxy aromatic A ring analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-$g...
|
|
WO/1993/018053A1 |
This invention provides a simplified method for converting pregnan-3,20-dione compounds to 3alpha-hydroxy,3beta-substituted-pregnanes. By selective use of reagents the unprotected dione is converted chemoselectively and diastereoselectiv...
|
|
WO/1993/015103A2 |
Novel steroids having a 9alpha-hydroxy or a 9alpha-carbonate substituent can be prepared from 9alpha-hydroxyandrostenedione and can be utilized in the synthesis of commercially valuable corticosteroids such as betamethasone. The 9alpha-c...
|
|
WO/1993/013123A1 |
Compounds of formula (I), wherein R17 and R'17 are such that: either R17 and R'17 together form ketone, hydrazono, oxime or methylene, or R17 is hydroxyl, hydroxymethyl or acyloxy and R'17 is hydrogen, alkyl or optionally substitued alke...
|
|
WO/1993/010141A2 |
Angiostatic steroids for use in controlling neovascularization and ocular hypertension are disclosed. Pharmaceutical compositions of the angiostatic steroids and methods for their use in treating neovascularization and ocular hypertensio...
|
|
WO/1993/003732A1 |
Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, insomnia and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-aminobutyric acid recept...
|
|
WO/1993/002095A1 |
In the field of organic chemistry, and therapeutical chemistry in particular, 6-substituted 19-nor pregnanes are provided which are selected from the group consisting of 6-substituted 3-keto-DELTA4-19-nor-pregnenes having partial formula...
|
|
WO/1993/000354A1 |
Described is a method for the preparation of 6-methylene steroids of general formula (I), in which X represents the CD ring system of the androstane-series or pregnane-series steroids, from steroids of general formula (II), in which X is...
|
|
WO/1992/022300A1 |
The invention relates to chemotherapy and concerns particularly the preparation of pharmaceutical compositions for ocular application, said compositions being characterized in that they contain at least one selected compound of steroidal...
|
|
WO/1992/015604A1 |
Compounds are provided which are highly selective inhibitors of the cytochrome P-450C17, commonly known as 17,20-lyase enzyme, responsible for androgen biosynthesis. These compounds can be administered to patients to inhibit the producti...
|
|
WO/1992/013873A1 |
Compounds of general formula (I), in which formula the 1,2-position is satured or is a double bond, R1 is hydrogen or a straight or branched hydrocarbon chain, R2 is a hydrogen or a straight or branched hydrocarbon chain, R3 is acyl, X1 ...
|
|
WO/1992/013872A1 |
Compounds of general formula (I) in the form of a 22R and 22S epimer, wherein X1 and X2 are the same or different and each represents a hydrogen atom or a fluorine atom, provided that X1 and X2 are not simultaneously a hydrogen atom, pro...
|
|
WO/1992/011277A1 |
Compounds have general formula (I), in which X stands for an oxygen atom or for the hydroxyimino grouping >N$m(k)OH; R?1¿ stands for a hydrogen atom or for a methyl group; G stands for a hydrogen, halogen atom, a C¿1?-C¿4? alkyl resid...
|
|
WO/1992/011278A1 |
New compounds having the general formula (I), as well as their pharmacologically acceptable addition salts with acids, are disclosed. In the formula (I), either (Ia) R?11¿ stands for a hydrogen atom in the $g(b) position, whereas R?12¿...
|
|
WO/1992/011279A1 |
A new type of D-homo-(16-en)-11$g(b)-aryl-4-estrenes having general formula (I), as well as their pharmacologically acceptable addition salts with acids are disclosed. In formula (I), X stands for an oxygen atom, the hydroxyimino groupin...
|
|
WO/1992/008730A1 |
A novel method is provided for crystallizing organic and particularly steroidal substances. In particular, a crystallization method is provided whereby a predeterminable and homogenous particle size class can be obtained non-mechanically...
|
|
WO/1992/001454A1 |
The present invention relates to the use of 20(R)-22-oxavitamin D analogues for treatment or prevention of skin ageing, and to the use of such compounds for preparation of pharmaceutical compositions for treatment and/or prevention of sk...
|
